Vitrafy Life Sciences's Cryopreservation Ecosystem Used In USAISR's Phase Two Platelet Cryopreservation Study, Shares Rise 5%

MT Newswires Live
04/08

Vitrafy Life Sciences (ASX:VFY) said the US Army Institute of Surgical Research (USAISR) completed the phase two testing of its platelet cryopreservation study using Vitrafy's cryopreservation ecosystem, according to a Wednesday Australian bourse filing.

The study sought to confirm the consistency of earlier results and further characterise performance across multiple cryopreservation formulations. The work was carried out under the ongoing cooperative research and development agreement (CRADA) between the firm and the US Army.

Its shares rose 5% in recent trading on Wednesday.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10